184 related articles for article (PubMed ID: 17603402)
1. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
[TBL] [Abstract][Full Text] [Related]
5. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Alaghband-Rad J; Hakimshooshtary M
Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
[TBL] [Abstract][Full Text] [Related]
7. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
8. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
[TBL] [Abstract][Full Text] [Related]
9. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
Besiroglu L; Çetinkaya N; Selvi Y; Atli A
Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
[TBL] [Abstract][Full Text] [Related]
10. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram in the treatment of obsessive-compulsive disorder.
Zohar J
Expert Rev Neurother; 2008 Mar; 8(3):339-49. PubMed ID: 18345966
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
[TBL] [Abstract][Full Text] [Related]
13. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
14. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
15. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
16. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
[TBL] [Abstract][Full Text] [Related]
17. Citalopram in refractory obsessive-compulsive disorder: an open study.
Marazziti D; Dell'Osso L; Gemignani A; Ciapparelli A; Presta S; Nasso ED; Pfanner C; Cassano GB
Int Clin Psychopharmacol; 2001 Jul; 16(4):215-9. PubMed ID: 11459335
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.
Dell'Osso B; Hadley S; Allen A; Baker B; Chaplin WF; Hollander E
J Clin Psychiatry; 2008 Mar; 69(3):452-6. PubMed ID: 18312057
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram prevents relapse of obsessive-compulsive disorder.
Fineberg NA; Tonnoir B; Lemming O; Stein DJ
Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial.
Khan MN; Hotiana UA; Ahmad S
J Ayub Med Coll Abbottabad; 2007; 19(4):58-63. PubMed ID: 18693600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]